Targeted therapy

From WikiProjectMed
Jump to navigation Jump to search
Targeted therapy
Other names: Molecularly targeted therapy
Targeted Therapy.svg
Individuals and their diseases are profiled in order to identify the most effective treatment for their specific case.
SpecialtyOncology

Targeted therapy or molecularly targeted therapy[1] is one of the major modalities of medical treatment (pharmacotherapy) for cancer,[2] others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth,[3] rather than by simply interfering with all rapidly dividing cells (e.g. with traditional chemotherapy). Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy. However, the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.[4][5]

Another form of targeted therapy involves the use of nanoengineered enzymes to bind to a tumor cell such that the body's natural cell degradation process can digest the cell, effectively eliminating it from the body.Targeted cancer therapies are expected to be more effective than older forms of treatments and less harmful to normal cells. Many targeted therapies are examples of immunotherapy developed by the field of cancer immunology. Thus, as immunomodulators, they are one type of biological response modifiers.[6][7]

The most successful targeted therapies are chemical entities that target or preferentially target a protein or enzyme that carries a mutation or other genetic alteration that is specific to cancer cells and not found in normal host tissue. One of the most successful molecular targeted therapeutic is Gleevec, which is a kinase inhibitor with exceptional affinity for the oncofusion protein BCR-Abl which is a strong driver of tumorigenesis in chronic myelogenous leukemia. Although employed in other indications, Gleevec is most effective targeting BCR-Abl. Other examples of molecular targeted therapeutics targeting mutated oncogenes, include PLX27892 which targets mutant B-raf in melanoma.[8][9][10]

There are targeted therapies for lung cancer, colorectal cancer, head and neck cancer, breast cancer, multiple myeloma, lymphoma, prostate cancer, pancreatic cancer, melanoma and other cancers.[2][11][12][13]

Biomarkers are usually required to aid the selection of patients who will likely respond to a given targeted therapy.[14]Co-targeted therapy involves the use of one or more therapeutics aimed at multiple targets, for example PI3K and MEK, in an attempt to generate a synergistic response[12] and prevent the development of drug resistance.[15][16]The definitive experiments that showed that targeted therapy would reverse the malignant phenotype of tumor cells involved treating Her2/neu transformed cells with monoclonal antibodies in vitro and in vivo by Mark Greene's laboratory and reported from 1985.[17]Some have challenged the use of the term, stating that drugs usually associated with the term are insufficiently selective.[18] Targeted therapies may also be described as "chemotherapy" or "non-cytotoxic chemotherapy", as "chemotherapy" strictly means only "treatment by chemicals".[19][20]

Types

Mechanism of imatinib

The main categories of targeted therapy are currently small molecules and monoclonal antibodies.

Small molecules

Many are tyrosine-kinase inhibitors.

Small molecule drug conjugates

Would be the following:

  • Vintafolide is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor. It is currently in clinical trials for platinum-resistant ovarian cancer (PROCEED trial) and a Phase 2b study (TARGET trial) in non-small-cell lung carcinoma (NSCLC).[54]

Serine/threonine kinase inhibitors (small molecules)

Would be the following:

Monoclonal antibodies

Monoclonal antibodies for cancer(ADEPT: antibody directed enzyme prodrug therapy; ADCC: antibody-dependent cell-mediated cytotoxicity; CDC: complement-dependent cytotoxicity; MAb, monoclonal antibody; scFv, single-chain Fv fragment)[60]

Several are in development and a few have been licensed by the FDA and the European Commission. Examples of licensed monoclonal antibodies include:

Targeted therapy progress

In the U.S., the National Cancer Institute's Molecular Targets Development Program (MTDP) aims to identify and evaluate molecular targets that may be candidates for drug development.[76][77]

The European Medicines Agency has given an accelerated assessment of several therapies, which include cell therapies for aggressive B-cell lymphomas[78] There are also several organizations which are pushing the research envelop on targeted therapy[79]

See also

References

  1. Min, Hye-Young; Lee, Ho-Young (October 2022). "Molecular targeted therapy for anticancer treatment". Experimental & Molecular Medicine. 54 (10): 1670–1694. doi:10.1038/s12276-022-00864-3. ISSN 2092-6413. Archived from the original on 2023-07-12. Retrieved 2024-01-24.
  2. 2.0 2.1 Cordo V, Meijerink J (January 2021). "T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies". Blood Cancer Discovery. 2: 19–31. doi:10.1158/2643-3230.BCD-20-0093.
  3. "Definition of targeted therapy – NCI Dictionary of Cancer Terms". Archived from the original on 2015-04-29. Retrieved 2021-09-20.
  4. Padma, Viswanadha Vijaya (28 November 2015). "An overview of targeted cancer therapy". BioMedicine. 5 (4): 19. doi:10.7603/s40681-015-0019-4. ISSN 2211-8020. Archived from the original on 20 September 2020. Retrieved 25 January 2024.
  5. Portillo, Peter Hofland, Sonia (22 March 2019). "What are Antibody-drug Conjugates? » ADC Review". ADC Review. Archived from the original on 23 October 2023. Retrieved 3 February 2024.
  6. Bag, Jagabandhu; Banerjee, Sabyasachi; De, Arnab; Manna, Sreejan; Banerjee, Subhasis; Kumar, S. K. Ashok; De, Sourav (16 October 2023). "Nanoengineered approaches to improve the efficacy of targeted drug delivery for the treatment of malignancy: a comprehensive review". Future Journal of Pharmaceutical Sciences. 9 (1): 88. doi:10.1186/s43094-023-00541-w. ISSN 2314-7253. Archived from the original on 28 January 2024. Retrieved 25 January 2024.
  7. Sindhu, Rakesh K.; Najda, Agnieszka; Kaur, Prabhjot; Shah, Muddaser; Singh, Harmanpreet; Kaur, Parneet; Cavalu, Simona; Jaroszuk-Sierocińska, Monika; Rahman, Md. Habibur (11 October 2021). "Potentiality of Nanoenzymes for Cancer Treatment and Other Diseases: Current Status and Future Challenges". Materials. 14 (20): 5965. doi:10.3390/ma14205965. ISSN 1996-1944. Archived from the original on 11 February 2024. Retrieved 4 February 2024.
  8. "How Gleevec Transformed Leukemia Treatment - NCI". www.cancer.gov. 2 February 2015. Archived from the original on 4 October 2023. Retrieved 1 February 2024.
  9. Neri, Camillo (9 December 2022). "Types and Methods Involved in Targeted Therapy to Tackle Cancer". Reports in Cancer and Treatment. 6 (6): 7–8. doi:10.4172/RepCancerTreat.6.6.001. Archived from the original on 25 March 2023. Retrieved 4 February 2024.
  10. Goldman, John M.; Melo, Junia V. (2008). "BCR-ABL in chronic myelogenous leukemia--how does it work?". Acta Haematologica. 119 (4): 212–217. doi:10.1159/000140633. ISSN 1421-9662. Archived from the original on 2022-01-21. Retrieved 2024-02-04.
  11. "Targeted Cancer Therapies". National Cancer Institute. Archived from the original on 2014-05-28. Retrieved 2021-09-20.
  12. 12.0 12.1 Heavey S, O'Byrne KJ, Gately K (April 2014). "Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC". Cancer Treatment Reviews. 40 (3): 445–56. doi:10.1016/j.ctrv.2013.08.006. PMID 24055012.
  13. Salem, Mohamed (30 November 2019). "Design, synthesis, biological evaluation and molecular modeling study of new thieno[2,3-d]pyrimidines with anti-proliferative activity on pancreatic cancer cell lines". Bioorganic Chemisry. 94: 103472. Archived from the original on 23 September 2021. Retrieved 20 September 2021 – via Elsevier Science Direct.
  14. Syn NL, Yong WP, Goh BC, Lee SC (August 2016). "Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review". Expert Opinion on Drug Metabolism & Toxicology. 12 (8): 911–22. doi:10.1080/17425255.2016.1196187. PMID 27249175. S2CID 205908189.
  15. Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, et al. (January 2018). "Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines". Scientific Reports. 8 (1): 1652. Bibcode:2018NatSR...8.1652H. doi:10.1038/s41598-018-19688-1. PMC 5786033. PMID 29374181.
  16. Heavey S, Godwin P, Baird AM, Barr MP, Umezawa K, Cuffe S, et al. (October 2014). "Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC". Cancer Biology & Therapy. 15 (10): 1367–77. doi:10.4161/cbt.29841. PMC 4130730. PMID 25025901.
  17. Perantoni AO, Rice JM, Reed CD, Watatani M, Wenk ML (September 1987). "Activated neu oncogene sequences in primary tumors of the peripheral nervous system induced in rats by transplacental exposure to ethylnitrosourea". Proceedings of the National Academy of Sciences of the United States of America. 84 (17): 6317–21. Bibcode:1987PNAS...84.6317P. doi:10.1073/pnas.84.17.6317. PMC 299062. PMID 3476947.
    Drebin JA, Link VC, Weinberg RA, Greene MI (December 1986). "Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen". Proceedings of the National Academy of Sciences of the United States of America. 83 (23): 9129–33. Bibcode:1986PNAS...83.9129D. doi:10.1073/pnas.83.23.9129. PMC 387088. PMID 3466178.
    Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI (July 1985). "Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies". Cell. 41 (3): 697–706. doi:10.1016/S0092-8674(85)80050-7. PMID 2860972. S2CID 26000048.
  18. Zhukov NV, Tjulandin SA (May 2008). "Targeted therapy in the treatment of solid tumors: practice contradicts theory". Biochemistry. Biokhimiia. 73 (5): 605–18. doi:10.1134/S000629790805012X. PMID 18605984. S2CID 1223977.
  19. Markman M (2008). "The promise and perils of 'targeted therapy' of advanced ovarian cancer". Oncology. 74 (1–2): 1–6. doi:10.1159/000138349. PMID 18536523. S2CID 44821306.
  20. "Targeted Therapy for Cancer - NCI". www.cancer.gov. 15 August 2014. Archived from the original on 6 November 2023. Retrieved 5 February 2024.
  21. "Imatinib Monograph for Professionals". Drugs.com. Archived from the original on 3 November 2023. Retrieved 28 January 2024.
  22. Johnson-Ansah, Hyacinthe; Maneglier, Benjamin; Huguet, Françoise; Legros, Laurence; Escoffre-Barbe, Martine; Gardembas, Martine; Cony-Makhoul, Pascale; Coiteux, Valérie; Sutton, Laurent; Abarah, Wajed; Pouaty, Camille; Pignon, Jean-Michel; Choufi, Bachra; Visanica, Sorin; Deau, Bénédicte; Morisset, Laure; Cayssials, Emilie; Molimard, Mathieu; Bouchet, Stéphane; Mahon, François-Xavier; Nicolini, Franck; Aegerter, Philippe; Cayuela, Jean-Michel; Delord, Marc; Bruzzoni-Giovanelli, Heriberto; Rousselot, Philippe (12 August 2022). "Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia". Pharmaceutics. 14 (8): 1676. doi:10.3390/pharmaceutics14081676. ISSN 1999-4923. Archived from the original on 11 February 2024. Retrieved 1 February 2024.
  23. "Gefitinib Monograph for Professionals". Drugs.com. Archived from the original on 2021-11-05. Retrieved 2024-01-28.
  24. Kumar, Pankaj; Mangla, Bharti; Javed, Shamama; Ahsan, Waquar; Musyuni, Pankaj; Ahsan, Aarif; Aggarwal, Geeta (2023). "Gefitinib: An Updated Review of its Role in the Cancer Management, its Nanotechnological Interventions, Recent Patents and Clinical Trials". Recent Patents on Anti-Cancer Drug Discovery. 18 (4): 448–469. doi:10.2174/1574892818666221026164940. ISSN 2212-3970. Archived from the original on 2023-12-02. Retrieved 2024-02-01.
  25. Katzel JA, Fanucchi MP, Li Z (January 2009). "Recent advances of novel targeted therapy in non-small cell lung cancer". Journal of Hematology & Oncology. 2 (1): 2. doi:10.1186/1756-8722-2-2. PMC 2637898. PMID 19159467.
  26. Lacroix, Marc (2014). Targeted Therapies in Cancer. Hauppauge, NY: Nova Sciences Publishers. ISBN 978-1-63321-687-7. Archived from the original on 2015-06-26. Retrieved 2021-09-20.
  27. "Sunitinib". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 26 September 2023. Retrieved 28 January 2024.
  28. "Dasatinib Monograph for Professionals". Drugs.com. Archived from the original on 10 December 2017. Retrieved 26 January 2024.
  29. "Lapatinib Monograph for Professionals". Drugs.com. Archived from the original on 26 January 2021. Retrieved 26 January 2024.
  30. "Nilotinib - NCI". www.cancer.gov. 1 February 2008. Archived from the original on 14 July 2021. Retrieved 26 January 2024.
  31. "Bortezomib Monograph for Professionals". Drugs.com. Archived from the original on 13 October 2019. Retrieved 28 January 2024.
  32. Sharma, Aarushi; Preuss, Charles V. (2024). "Bortezomib". StatPearls. StatPearls Publishing. Archived from the original on 2024-02-11. Retrieved 2024-02-02.
  33. Jordan VC (January 2008). "Tamoxifen: catalyst for the change to targeted therapy". European Journal of Cancer. 44 (1): 30–8. doi:10.1016/j.ejca.2007.11.002. PMC 2566958. PMID 18068350.
  34. "Tofacitinib Monograph for Professionals". Drugs.com. Archived from the original on 28 September 2021. Retrieved 27 January 2024.
  35. "Xalkori | European Medicines Agency". www.ema.europa.eu. Archived from the original on 19 April 2021. Retrieved 27 January 2024.
  36. Warr MR, Shore GC (December 2008). "Small-molecule Bcl-2 antagonists as targeted therapy in oncology". Current Oncology. 15 (6): 256–61. doi:10.3747/co.v15i6.392. PMC 2601021. PMID 19079626.
  37. "Olaparib (Lynparza) for the treatment of advanced breast cancer: Overview". InformedHealth.org [Internet]. Institute for Quality and Efficiency in Health Care (IQWiG). 29 October 2019. Archived from the original on 11 February 2024. Retrieved 29 January 2024.
  38. Dockery, L. E.; Gunderson, C. C.; Moore, K. N. (2017). "Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer". OncoTargets and Therapy. 10: 3029–3037. doi:10.2147/OTT.S114714. ISSN 1178-6930. Archived from the original on 2022-06-15. Retrieved 2024-02-02.
  39. Kondapaka, SB; Singh, SS; Dasmahapatra, GP; Sausville, EA; Roy, KK (November 2003). "Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation". Molecular cancer therapeutics. 2 (11): 1093–103. PMID 14617782. Archived from the original on 28 January 2024. Retrieved 27 January 2024.
  40. Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, et al. (October 2010). "Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies". BMC Cancer. 10: 529. doi:10.1186/1471-2407-10-529. PMC 2984425. PMID 20923544.
  41. "Apatinib". clinicaltrials.gov. Archived from the original on 2011-06-13. Retrieved 2021-09-20.
  42. "Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer". 2010. Archived from the original on 2012-03-23. Retrieved 2021-09-20.
  43. "Dabrafenib". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 19 August 2022. Retrieved 29 January 2024.
  44. Khaddour, Karam; Kurn, Heidi; Zito, Patrick M. (2024). "Vemurafenib". StatPearls. StatPearls Publishing. Archived from the original on 2024-02-11. Retrieved 2024-02-03.
  45. "Mekinist | European Medicines Agency". www.ema.europa.eu. Archived from the original on 9 August 2021. Retrieved 29 January 2024.
  46. Ascierto, Paolo A.; Schadendorf, Dirk; Berking, Carola; Agarwala, Sanjiv S.; van Herpen, Carla Ml; Queirolo, Paola; Blank, Christian U.; Hauschild, Axel; Beck, J. Thaddeus; St-Pierre, Annie; Niazi, Faiz; Wandel, Simon; Peters, Malte; Zubel, Angela; Dummer, Reinhard (March 2013). "MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study". The Lancet. Oncology. 14 (3): 249–256. doi:10.1016/S1470-2045(13)70024-X. ISSN 1474-5488. Archived from the original on 2023-10-03. Retrieved 2024-02-02.
  47. "Sonidegib". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 1 October 2023. Retrieved 30 January 2024.
  48. Zito, Patrick M.; Nassereddin, Ali; Scharf, Richard (2024). "Vismodegib". StatPearls. StatPearls Publishing. Archived from the original on 2023-01-07. Retrieved 2024-02-02.
  49. Wang, Hui; Zhang, Hongyi; Zhu, Yihao; Wu, Zhonghang; Cui, Chunhong; Cai, Fengfeng (2021). "Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications". Frontiers in Oncology. 11. doi:10.3389/fonc.2021.654428/full. ISSN 2234-943X. Archived from the original on 23 January 2024. Retrieved 28 January 2024.
  50. Zhou, Shuang; Wang, Fengfei; Wong, Eric T.; Fonkem, Ekokobe; Hsieh, Tze-Chen; Wu, Joseph M.; Wu, Erxi (2013). "Salinomycin: A Novel Anti-Cancer Agent with Known Anti-Coccidial Activities". Current medicinal chemistry. 20 (33): 4095–4101. ISSN 0929-8673. Archived from the original on 2022-12-05. Retrieved 2024-01-31.
  51. "Molecular mechanisms of dianhydrogalactitol (VAL-083) in overcoming chemoresistance in glioblastoma". American Association for Cancer Research. Beibei Zhai, Anna Gobielewska, Anne Steino, Jeffrey A. Bacha, Dennis M. Brown, Simone Niclou and Mads Daugaard. Archived from the original on 2021-09-23. Retrieved 2021-09-20.
  52. "DNA damage response to dianhydrogalactitol (VAL-083) in p53-deficient non-small cell lung cancer cells". American Association for Cancer Research. Anne Steino, Guangan He, Jeffrey A. Bacha, Dennis M. Brown and Zahid Siddik. Archived from the original on 2021-04-30. Retrieved 2021-09-20.
  53. "VAL-083 Clinical Trials". ClinicalTrials.Gov. U.S. National Institutes of Health. Archived from the original on 2021-04-29. Retrieved 2021-09-20.
  54. "Merck, Endocyte in Development Deal". dddmag.com. 25 April 2012. Archived from the original on 12 June 2018. Retrieved 20 September 2021.
  55. "Temsirolimus Monograph for Professionals". Drugs.com. Archived from the original on 2 March 2015. Retrieved 27 January 2024.
  56. "Everolimus Monograph for Professionals". Drugs.com. Archived from the original on 17 April 2021. Retrieved 27 January 2024.
  57. "Vemurafenib Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 27 January 2024.
  58. "Mekinist | European Medicines Agency". www.ema.europa.eu. Archived from the original on 9 August 2021. Retrieved 27 January 2024.
  59. "Dabrafenib". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 19 August 2022. Retrieved 27 January 2024.
  60. Modified from Carter P (November 2001). "Improving the efficacy of antibody-based cancer therapies". Nature Reviews. Cancer. 1 (2): 118–29. doi:10.1038/35101072. PMID 11905803. S2CID 10169378.
  61. "Keytruda". National Cancer Institute. 2011-02-02. Archived from the original on 2021-04-29. Retrieved 2021-09-20.
  62. "Pembrolizumab Use in Cancer". National Cancer Institute. 2014-09-18. Archived from the original on 2018-01-23. Retrieved 2021-09-20.
  63. "Rituximab Monograph for Professionals". Drugs.com. Archived from the original on 2016-03-27. Retrieved 2024-01-28.
  64. Hanif, Nazma; Anwer, Faiz (2024). "Rituximab". StatPearls. StatPearls Publishing. Archived from the original on 2023-10-15. Retrieved 2024-01-31.
  65. "Trastuzumab Monograph for Professionals". Drugs.com. Archived from the original on 2016-12-21. Retrieved 2024-01-28.
  66. Greenblatt, Karl; Khaddour, Karam (2024). "Trastuzumab". StatPearls. StatPearls Publishing. Archived from the original on 2023-10-13. Retrieved 2024-01-31.
  67. "Alemtuzumab Monograph for Professionals". Drugs.com. Archived from the original on 2012-01-28. Retrieved 2024-01-28.
  68. "Therascreen KRAS RGQ PCR Kit – P110030“. Device Approvals and Clearances. U.S. Food and Drug Administration. 2012-07-06.
  69. European medicines Agency (June 2014). “Erbitux® Summary of Product Characteristics (PDF).“ 2015-11-19.
  70. “Cetuximab (Erbitux). About the Center of Drug Evaluation and Research." U.S. Food and Drug Administration. Archived 2017-01-18 at the Wayback Machine 2015-11-16.
  71. "Merck KGaA: European Commission Approves Erbitux for First-Line Use in Head and Neck Cancer" 2015-11-16
  72. "Vectibix | European Medicines Agency". www.ema.europa.eu. Archived from the original on 2021-08-13. Retrieved 2024-01-28.
  73. Kast, Johannes; Dutta, Sandeep; Upreti, Vijay V. (July 2021). "Panitumumab: A Review of Clinical Pharmacokinetic and Pharmacology Properties After Over a Decade of Experience in Patients with Solid Tumors". Advances in Therapy. 38 (7): 3712–3723. doi:10.1007/s12325-021-01809-4. ISSN 1865-8652. Archived from the original on 21 June 2021. Retrieved 31 January 2024.
  74. Pollack, Andrew (2009-03-31). "F.D.A. Panel Supports Avastin to Treat Brain Tumor". New York Times. Archived from the original on 2009-04-01. Retrieved 2009-08-13.
  75. "Ipilimumab Monograph for Professionals". Drugs.com. Archived from the original on 2021-05-06. Retrieved 2024-01-28.
  76. Montoya, Skye; Soong, Deborah; Nguyen, Nina; Affer, Maurizio; Munamarty, Sailasya P.; Taylor, Justin (November 2021). "Targeted Therapies in Cancer: To Be or Not to Be, Selective". Biomedicines. 9 (11). doi:10.3390/biomedicines9111591. Archived from the original on 2024-02-11. Retrieved 2024-01-30.
  77. "NCI's molecular targets development program (MTDP)". aacrjournals.org. Archived from the original on 2024-02-11. Retrieved 2024-02-05.
  78. Loche, Alberto. "Opportunities and challenges for Cell Gene Therapies in Pharmaceuticals and Medical Products in Europe | McKinsey". www.mckinsey.com. Archived from the original on 2 October 2023. Retrieved 5 February 2024.
  79. Smeltzer, Matthew P.; Wynes, Murry W.; Lantuejoul, Sylvie; Soo, Ross; Ramalingam, Suresh S.; Varella-Garcia, Marileila; Meadows Taylor, Meghan; Richeimer, Kristin; Wood, Kelsey; Howell, Kristen E.; Dalurzo, Mercedes Lilana; Felip, Enriqueta; Hollenbeck, Gina; Kerr, Keith; Kim, Edward S.; Mathias, Clarissa; Pacheco, Jose; Postmus, Pieter; Powell, Charles; Tsuboi, Masahiro; Wistuba, Ignacio I.; Wakelee, Heather A.; Belani, Chandra P.; Scagliotti, Giorgio V.; Hirsch, Fred R. (September 2020). "The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer". Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer. 15 (9): 1434–1448. doi:10.1016/j.jtho.2020.05.002. ISSN 1556-1380. Archived from the original on 22 December 2022. Retrieved 5 February 2024.

External links